Home | Business News | CBJ Newsmakers | Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer RecommendedPattieSwap Ready to Launch a Top DEX With Low FeesDynamic Technologies Announces Termination of Sales and Investment Solicitation Process and Extension of StayBULGOLDĀ Announces Refiling of First Quarter Financial Results for Three Months Ended March 31, 2023
